ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Vernalis Slashes jobs After Setback

February 25, 2008 | APPEARED IN VOLUME 86, ISSUE 8

Vernalis, a British biopharmaceutical company, is cutting its staff from 210 people to about 90 and is closing its clinical development operations in Canada. Vernalis will also settle an $82 million loan with its partner, Endo Pharmaceuticals. The news, which follows FDA's refusal to approve its drug Frova for the treatment of menstrual migraine, is spurring speculation that the company may be a takeover target. Vernalis currently has drug candidates in clinical trials for Parkinson's disease, ischemic stroke, neuropathic pain, and obesity. It also has an R&D collaboration with Biogen Idec on a Parkinson's disease drug and separate ventures with Novartis and Servier on cancer therapies.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment